MEGGA
BIOTICS
Redefining Biotechnology’s Purpose: They MAX profits, we FYX people.
JOHN HARE
01
Services
Precision
MEGGABIOTICS®: A First-in-Class Therapy
Unlike antibiotics or probiotics, our patented Microbiome EGG Antibody Therapy uses targeted IgY antibodies from hens to neutralize harmful pathogens without disrupting beneficial bacteria—offering a safe, nutritionally enhanced solution to restore gut balance and address chronic diseases at their root.
28 Years of Validated Science
From Livestock to Human Trials
After pioneering the world’s first veterinary biologic for E. coli in 2007, we’re now advancing Phase 2 human trials for C. difficile infections, with potential to transform care for autoimmune disorders, metabolic diseases, and inflammatory conditions.
Sustainable, Scalable, and Patented
Nature’s Bioreactors Meet Cutting-Edge Science
By harnessing hyperimmunized hens for antibody production, we deliver an eco-friendly, orally administered therapy that prioritizes safety, affordability, and global accessibility—proving healing innovation can align with ethical stewardship.
About us
Advancing Breakthroughs in Biotechnology for a Healthier Global Future
Combining a validated 28-year track record—including the world’s first veterinary biologic for E. coli (2007) and Phase 2 trials for C. difficile—with a pioneering fusion of antibody therapy, nutrition, and microbiome science, MEGGABIOTICS transcends traditional “biotic” approaches to address chronic diseases at their root.